Fremanezumab for Migraine Shows Impressive Results

By Bob Kronemyer

Subcutaneous injections of the experimental migraine drug fremanezumab at monthly or quarterly intervals provided rapid and sustained relief for both chronic and episodic migraine, according to the results of two pivotal phase 3 studies.

“There have been no new treatments developed specifically to prevent migraine over the past 20 years, which is surprising, considering it is one of the foremost disabling diseases,” said Ernesto Aycardi, MD, vice president of research